Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06106347
Other study ID # Soh-Med-23-10-02MS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 15, 2023
Est. completion date October 15, 2024

Study information

Verified date October 2023
Source Sohag University
Contact Mostafa R Refaee, Resident
Phone 01125795711
Email refatsasa3@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The digital technology is universal and has spread worldwide; thus, digital behaviour has dramatically changed peoples' lifestyles. Previous studies have reported that individuals interact with digital screens for up to 12 hours daily,1,2 and the American Optometric Association defined a combination of ocular and extraocular symptoms that affects the screen users as computer vision syndrome (CVS).3 However, our current understanding of digital technology and its harmful impact on the eye and public health,1,4,5 visual performance,6-8 sleep patterns,7,8 circadian rhythms,5,8 musculoskeletal system activities,3,4 and underlying physiological mechanisms9 remains incomplete and is associated with misconceptions.1 Therefore, educational programs that include protective measures and health campaigns are necessary.10 Computer vision syndrome (CVS) is also called with other names as digital eye strain (DES),3 occupational asthenopia, digital asthenopia,1 and video display terminal syndrome (VDTS). CVS ocular symptoms include visual blur with an underlying mechanism that is not fully understood,10 dry eye disease (DED),3 eye redness and irritation, eyestrain, fatigue, discomfort, difficulty in refocusing the eyes, and diplopia.3,4. CVS extraocular symptoms include headache, sleep disturbances, depression,7,8 musculoskeletal aches, such as neck/shoulder/back pain, difficulty in writing or holding objects, pain in thumbs, fingers, or wrists because of tendonitis and/or arthritis. Smartphones are used extensively worldwide by people of all ages, and have close-viewing distance, related high-definition resolution, thousands of time-consuming applications and games in stores, and 24/7 Internet connectivity. The decline in visual acuity observed in CVS can be attributed to the screen-induced foveal dysfunction11-13 which is a phenomenon that has been extensively documented in the literature using multifocal electroretinogram (mfERG) examinations. Previous studies11-13 consistently reported the presence of this dysfunction, which has been linked to prolonged exposure to digital screens emitting blue light. Notably, recent research has demonstrated noteworthy improvements in foveal responses following a strict reduction in screen time for duration of four weeks.13 These improvements were found to correspond with enhanced visual performances, indicating a positive relationship between the reversal of screen-induced foveal dysfunction and visual outcomes. These findings highlight the reversible nature of screen-induced foveal dysfunction and its potential impact on visual acuity. They support the notion that reducing screen time can serve as an effective intervention strategy, leading to substantial improvements in both foveal responses and overall visual performance.13 The computer vision syndrome questionnaire (CVS-Q) is a self-administered scale that evaluates the frequency and intensity of 16 ocular and visual symptoms related to the use of digital devices. The scoring of the questionnaire follows the procedure of the original version. The 16 items (CVS-symptoms) are scored with two rating scales: one for frequency (never, occasionally, often, or always), and one for intensity (moderate, intense). The responses to the two rating scales for each item are combined multiplicatively into a single scale called symptom severity, and the result should be recoded as 0 = 0; 1 or 2 = 1; 4 = 2. If the total score is ≥ 6 points, the worker is considered to suffer computer vision syndrome .14 Ocular surface disease index is a quick self-assessment questionnaire of the symptoms of ocular irritation in dry eye disease (DED) and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effect it has on vision-related function in the past week of the patient's life.15 The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.15 DED, also known as keratoconjunctivitis sicca, is the condition of having dry eyes. Symptoms include dryness in the eye, irritation, redness, discharge, blurred vision, and easily fatigued eyes. Symptoms range from mild and occasional to severe and continuous. DED can lead to blurred vision, instability of the tear film, increased risk of damage to the ocular surface such as scaring of the cornea, and changes in the eye including the neurosensory system.16


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 15, 2024
Est. primary completion date October 15, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 30 Years
Eligibility Inclusion Criteria: - include university students and young staff members, 20-30 years old who were spending more than 3 screen-hours daily on average over the last 3 years. Exclusion Criteria: - include amblyopia; strabismus; anisometropia; refractive errors higher than 4 D myopia, 4 D hyperopia, or 4 D astigmatism; difference between subjective and cycloplegic refraction >1D; and previous or current systemic or eye disease or surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)
physiological macular function

Locations

Country Name City State
Egypt Sohag University hospitals Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Ahmed SF, McDermott KC, Burge WK, Ahmed IIK, Varma DK, Liao YJ, Crandall AS, Khaderi SKR. Visual function, digital behavior and the vision performance index. Clin Ophthalmol. 2018 Dec 10;12:2553-2561. doi: 10.2147/OPTH.S187131. eCollection 2018. — View Citation

Iqbal M, Said O, Ibrahim O, Soliman A. Visual Sequelae of Computer Vision Syndrome: A Cross-Sectional Case-Control Study. J Ophthalmol. 2021 Apr 2;2021:6630286. doi: 10.1155/2021/6630286. eCollection 2021. — View Citation

Iqbal M, Soliman A, Ibrahim O, Gad A. Analysis of the Outcomes of the Screen-Time Reduction in Computer Vision Syndrome: A Cohort Comparative Study. Clin Ophthalmol. 2023 Jan 7;17:123-134. doi: 10.2147/OPTH.S399044. eCollection 2023. — View Citation

Vaz FT, Henriques SP, Silva DS, Roque J, Lopes AS, Mota M. Digital Asthenopia: Portuguese Group of Ergophthalmology Survey. Acta Med Port. 2019 Apr 30;32(4):260-265. doi: 10.20344/amp.10942. Epub 2019 Apr 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary nV/deg2 physiological macular function 12 months
See also
  Status Clinical Trial Phase
Completed NCT05699057 - Tendency to Suicide as a Sequel of Computer Vision Syndrome
Completed NCT05211063 - Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders N/A
Completed NCT05070767 - Neurolens Headache Study N/A
Terminated NCT05087563 - Neurolens Convergence Insufficiency Study N/A
Completed NCT04405648 - Computer Vision Syndrome Prevalence Among University Students
Completed NCT04398212 - Computer Vision Syndrome Visual Sequelae N/A
Recruiting NCT05414799 - Effect of Exercises on Computer Vision Syndrome N/A
Not yet recruiting NCT06163989 - Protecting the Eyes of Gamers With Lubricating Eyedrops N/A
Completed NCT03831919 - Trial of Hoya SYNC III Design Lenses N/A
Completed NCT05151302 - The Italian Version of the Computer-Vision Symptom Scale Questionnaire: Translation, Validation and Reliability. N/A
Recruiting NCT04668118 - The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye Phase 4
Completed NCT05187221 - Prevalence and Sequelae of Computer Vision Syndrome in Egyptian Universities
Recruiting NCT05545878 - Impact of 'SESL01' Lens on Computer Vision Syndrome N/A
Completed NCT04637516 - Evaluation of an Updated Version of the Program "BlinkBlink" for Alleviation of Dry Eye Symptoms Induced by Computer Work N/A